Q3 FY26 results: revenue 5,748 cr, 9M PAT up 71%; MD re-appointed
PARADEEP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.0 pts less than Nifty Smallcap 250 and 2.7 pts less than its Fertilizers peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Board approved Q3 and 9M FY26 results, restated for MCFL merger. Q3 revenue 5,748.67 cr, up 15% YoY; 9M revenue 17,124.37 cr, up 34%. Q3 PAT 182.05 cr vs 209.28 cr (down 13% due to 41.30 cr Labour Code exceptional charge). 9M PAT up 71% to 841.24 cr. EPS Q3 at 1.76. MD Suresh Krishnan re-appointed for 3 years; K K Rajeev Nambiar named Joint MD from April 1, 2026. BSR and Co issued unmodified review with emphasis on merger restatement.
Strong 9M growth on restated basis (revenue up 34%, PAT up 71%). Q3 dip is from one-time Labour Code charge. Leadership continuity maintained.